Acadian Asset Management
SGMO

Acadian Asset Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Acadian Asset Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-4,560,770
Closed -$1.63M – 2308
2024
Q2 		$1.63M Sell
4,560,770
-382,490
-8% -$207K 0.01% 834
2024
Q1 		$3.31M Buy
4,943,260
+192,385
+4% +$140K 0.01% 556
2023
Q4 		$2.58M Buy
4,750,875
+1,823,106
+62% +$840K 0.01% 609
2023
Q3 		$1.75M Buy
2,927,769
+105,789
+4% +$113K 0.01% 722
2023
Q2 		$3.67M Buy
2,821,980
+2,353,741
+503% +$3.22M 0.02% 538
2023
Q1 		$822K Buy
+468,239
New +$1.34M ﹤0.01% 929
2021
Q2 		– Sell
-9,925
Closed -$124K – 2190
2021
Q1 		$124K Buy
9,925
+3,240
+48% +$43.7K ﹤0.01% 1622
2020
Q4 		$104K Buy
+6,685
New +$78.3K ﹤0.01% 1739
2017
Q4 		– Sell
-44,862
Closed -$673K – 1666
2017
Q3 		$673K Buy
+44,862
New +$496K ﹤0.01% 741

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Acadian Asset Management's SGMO Position: Q3 2024 in Review

Acadian Asset Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 4,560,770 shares — an estimated $1.63M sold.

Acadian Asset Management first reported a position in SGMO in Q3 2017 and held it in 9 quarters. The position peaked at $3.67M in Q2 2023. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • Acadian Asset Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Acadian Asset Management sold 4,560,770 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $1.63M.
  • Acadian Asset Management first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and held it in 9 quarters.
  • Acadian Asset Management's SANGAMO THERAPEUTICS INC position peaked at $3.67M in Q2 2023.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Acadian Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.